Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mari Manuia

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|October 27, 2015
HTRF Kinase Assay Development and Methods in Inhibitor CharacterizationYong Jia, Mari Manuia, Jose Juarez
Proceedings of the National Academy of Sciences of the United States of America|May 16, 2008
Superoxide dismutase 1 (SOD1) is essential for H2O2-mediated oxidation and inactivation of phosphatases in growth factor signalingJose C Juarez, Mari Manuia, Mark E Burnett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2008
Pharmacology of the novel antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2): observation of a U-shaped dose-response curve in several preclinical models of angiogenesis and tumor growthFernando Doñate, Graham C Parry, Yuval Shaked, et al.
RSC Chemical Biology|February 6, 2026
High-throughput assay for measuring target occupancy of covalent compounds: a case study with MK2Julian L Wong, Mari Manuia, Sandra Gao, et al.
Journal of Medicinal Chemistry|April 6, 2021
Structure-Based Design of Selective LONP1 Inhibitors for Probing <i>In Vitro</i> BiologyLaura J Kingsley, Xiaohui He, Matthew McNeill, et al.
Journal of Medicinal Chemistry|July 20, 2016
Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung CancersGérald Lelais, Robert Epple, Thomas H Marsilje, et al.
Nature|June 3, 2016
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitorsYong Jia, Cai-Hong Yun, Eunyoung Park, et al.
Cancer Research|January 31, 2016
EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF ReceptorYong Jia, Jose Juarez, Jie Li, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Methods in Molecular Biology (Clifton, N.J.)|October 27, 2015
HTRF Kinase Assay Development and Methods in Inhibitor CharacterizationYong Jia, Mari Manuia, Jose Juarez
Proceedings of the National Academy of Sciences of the United States of America|May 16, 2008
Superoxide dismutase 1 (SOD1) is essential for H2O2-mediated oxidation and inactivation of phosphatases in growth factor signalingJose C Juarez, Mari Manuia, Mark E Burnett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2008
Pharmacology of the novel antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2): observation of a U-shaped dose-response curve in several preclinical models of angiogenesis and tumor growthFernando Doñate, Graham C Parry, Yuval Shaked, et al.
RSC Chemical Biology|February 6, 2026
High-throughput assay for measuring target occupancy of covalent compounds: a case study with MK2Julian L Wong, Mari Manuia, Sandra Gao, et al.
Journal of Medicinal Chemistry|April 6, 2021
Structure-Based Design of Selective LONP1 Inhibitors for Probing <i>In Vitro</i> BiologyLaura J Kingsley, Xiaohui He, Matthew McNeill, et al.
Journal of Medicinal Chemistry|July 20, 2016
Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung CancersGérald Lelais, Robert Epple, Thomas H Marsilje, et al.
Nature|June 3, 2016
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitorsYong Jia, Cai-Hong Yun, Eunyoung Park, et al.
Cancer Research|January 31, 2016
EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF ReceptorYong Jia, Jose Juarez, Jie Li, et al.
Pageof 1